ClinicalTrials.gg
CompletedNCT00436527Updated Jul 29, 2022

Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application

A Phase 4 interventional study of Metronidazole gel 1% in Rosacea, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-29.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Rosacea by Galderma Group AG — none open to participants now, none under way, none of them phase 3. Rosacea · Galderma Group AG.

Enrollment
22nd of 24
26 · median 198
Started
2006
the only one that year
Phase 4
9 of 28
none open now
Registered
3rd of 28
by date

Among the 28 studies in Rosacea by Galderma Group AG, this one is the 22nd largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2006, is one of 9 in phase 4, and was the 3rd registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 28 studies in Rosacea by Galderma Group AG is open now. The open studies under Rosacea, anywhere →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Rosacea by Galderma Group AG as a file.
02

Study summary

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.

Read the detailed description

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application as measured by the Corneometer CM 825.

03

Conditions studied

  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of moderate to severe rosacea, defined as the presence of at least moderate erythema with telangiectasia and a minimum of two inflammatory lesions

Exclusion criteria

Exclusion Criteria:

  • Individuals with active symptoms of allergy (mild active seasonal allergies are acceptable) or atopic dermatitis
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Other
    1

    Drug: Metronidazole gel 1%

Interventions

  • Applied once to a test site on the right or left cheek (as determined by a randomization design)

    Also known as: MetroGel® 1%

06

What researchers measure

Primary outcomes

  1. Six replicate Corneometer CM 825 measurements

    Time frame: 8 hours

Secondary outcomes

  1. Adverse events

    Time frame: 1 day

07

Study locations

1 site
  • Colorado Springs Research Center
    Colorado Springs, Colorado 80915, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2007
First posted
Feb 19, 2007
Start
Aug 2006
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Last update
Jul 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00436527
Lead sponsor
Galderma R&D
First posted
Feb 19, 2007
Start date
Aug 2006
Primary completion
Aug 2006
Completion
Aug 2006
Last update
Jul 29, 2022

Study contacts

Ronald W Gottschalk, MD
study director · Galderma Laboratories, LP

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion